SINTX Technologies Sells Technology Assesment and Transfer Subsidiary to Focus on Medical Device Market
SINTX Technologies (NASDAQ: SINT) has announced the sale of its subsidiary, Technology Assessment and Transfer (TA&T), to Tethon This strategic move aims to streamline operations and focus on the medical device sector, particularly in bioceramic technologies for healthcare applications.
The transaction provides significant financial benefits, reducing corporate liabilities by $750,000 and cutting annual operating expenses by over $1.7 million. The company will concentrate on commercializing its silicon nitride-based technologies, which have been utilized in human implants since 2008.
According to CEO Eric K. Olson, this divestment represents a strategic realignment that will enable SINTX to commit its resources fully to the medical device market, where their advanced ceramics expertise can make the most significant impact.
SINTX Technologies (NASDAQ: SINT) ha annunciato la vendita della sua controllata, Technology Assessment and Transfer (TA&T), a Tethon. Questa mossa strategica mira a semplificare le operazioni e a concentrarsi sul settore dei dispositivi medici, in particolare nelle tecnologie bioceramiche per applicazioni sanitarie.
La transazione offre vantaggi finanziari significativi, riducendo le passività aziendali di $750.000 e abbattendo le spese operative annuali di oltre $1,7 milioni. L'azienda si concentrerà sulla commercializzazione delle sue tecnologie a base di nitruro di silicio, utilizzate negli impianti umani dal 2008.
Secondo il CEO Eric K. Olson, questa dismissione rappresenta un riallineamento strategico che permetterà a SINTX di dedicare completamente le proprie risorse al mercato dei dispositivi medici, dove la loro esperienza nelle ceramiche avanzate può avere il maggiore impatto.
SINTX Technologies (NASDAQ: SINT) ha anunciado la venta de su filial, Technology Assessment and Transfer (TA&T), a Tethon. Este movimiento estratégico tiene como objetivo simplificar las operaciones y centrarse en el sector de dispositivos médicos, particularmente en tecnologías biocerámicas para aplicaciones en salud.
La transacción proporciona beneficios financieros significativos, reduciendo las responsabilidades corporativas en $750,000 y recortando los gastos operativos anuales en más de $1.7 millones. La empresa se concentrará en comercializar sus tecnologías basadas en nitruro de silicio, que se han utilizado en implantes humanos desde 2008.
Según el CEO Eric K. Olson, esta desinversión representa un reajuste estratégico que permitirá a SINTX comprometer completamente sus recursos al mercado de dispositivos médicos, donde su experiencia en cerámicas avanzadas puede tener el mayor impacto.
SINTX 테크놀로지스 (NASDAQ: SINT)는 자회사인 기술 평가 및 이전(Technology Assessment and Transfer, TA&T)을 테톤(Tethon)에게 매각했다고 발표했습니다. 이 전략적 결정은 운영을 간소화하고 의료 기기 부문, 특히 의료 응용을 위한 바이오세라믹 기술에 집중하기 위한 것입니다.
이번 거래는 $750,000의 기업 부채를 줄이고 연간 운영 비용을 $1.7백만 이상 절감하는 등 상당한 재정적 이점을 제공합니다. 이 회사는 2008년부터 인체 이식에 사용되어 온 실리콘 나이트라이드 기반 기술의 상용화에 집중할 것입니다.
CEO 에릭 K. 올슨(Eric K. Olson)에 따르면, 이번 매각은 SINTX가 의료 기기 시장에 자원을 전적으로 투입할 수 있게 하는 전략적 재편성을 나타내며, 이곳에서 그들의 첨단 세라믹 전문성이 가장 큰 영향을 미칠 수 있습니다.
SINTX Technologies (NASDAQ: SINT) a annoncé la vente de sa filiale, Technology Assessment and Transfer (TA&T), à Tethon. Ce mouvement stratégique vise à rationaliser les opérations et à se concentrer sur le secteur des dispositifs médicaux, en particulier dans les technologies biocéramiques pour les applications de santé.
La transaction offre des avantages financiers significatifs, réduisant les passifs de l'entreprise de $750,000 et diminuant les dépenses d'exploitation annuelles de plus de $1,7 million. L'entreprise se concentrera sur la commercialisation de ses technologies à base de nitrure de silicium, qui sont utilisées dans les implants humains depuis 2008.
Selon le PDG Eric K. Olson, cette cession représente un réalignement stratégique qui permettra à SINTX de consacrer pleinement ses ressources au marché des dispositifs médicaux, où leur expertise en céramiques avancées peut avoir le plus grand impact.
SINTX Technologies (NASDAQ: SINT) hat den Verkauf seiner Tochtergesellschaft, Technology Assessment and Transfer (TA&T), an Tethon angekündigt. Dieser strategische Schritt zielt darauf ab, die Abläufe zu straffen und sich auf den Bereich der medizinischen Geräte zu konzentrieren, insbesondere auf biokeramische Technologien für Gesundheitsanwendungen.
Die Transaktion bietet erhebliche finanzielle Vorteile, indem die Unternehmensverbindlichkeiten um $750.000 gesenkt und die jährlichen Betriebskosten um über $1,7 Millionen reduziert werden. Das Unternehmen wird sich darauf konzentrieren, seine auf Siliziumnitrid basierenden Technologien zu kommerzialisieren, die seit 2008 in menschlichen Implantaten eingesetzt werden.
Nach Angaben von CEO Eric K. Olson stellt diese Veräußerung eine strategische Neuausrichtung dar, die es SINTX ermöglicht, seine Ressourcen vollständig auf den Markt für medizinische Geräte zu konzentrieren, wo ihre Expertise in fortschrittlichen Keramiken den größten Einfluss haben kann.
- Reduction in corporate liabilities by $750,000
- Annual operating expenses decreased by $1.7 million
- Strategic focus on high-growth medical device sector
- Streamlined operations for better operational efficiency
- Divestment of revenue-generating subsidiary
- Reduced business diversification
Insights
The strategic sale of Technology Assessment and Transfer (TA&T) marks a pivotal transformation for SINTX Technologies, yielding both immediate and long-term benefits. The transaction's financial impact is substantial, with
The divestment represents more than just cost optimization; it's a strategic realignment that positions SINTX to capitalize on the rapidly growing medical device market, projected to reach
The streamlined operational structure should accelerate product development cycles and time-to-market for new medical innovations. This focus is particularly valuable in the current healthcare environment, where innovative biomaterials are increasingly important for improving patient outcomes. The reduction in operational complexity could also enhance SINTX's appeal to potential strategic partners or investors in the medical device space.
However, investors should note that this strategic pivot, while promising, also concentrates market risk. The success of this strategy will largely depend on SINTX's ability to accelerate commercialization of its medical device pipeline and effectively deploy the improved financial flexibility toward revenue-generating opportunities in healthcare.
Strategic Transaction Enhances Financial Flexibility and Supports Growth in Healthcare Innovations
Salt Lake City, UT, Feb. 20, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT), a leader in advanced ceramics for medical applications, today announced the sale of its wholly-owned subsidiary, Technology Assessment and Transfer (TA&T), to Tethon Corporation DBA Tethon 3D (Tethon). This transaction marks a significant step in SINTX’s ongoing transformation, allowing the Company to sharpen its focus on high-growth opportunities in the medical device sector while improving its financial position and operational efficiency.
The divestment aligns with SINTX’s refined strategy to accelerate innovation in the healthcare space. With this sale, SINTX is streamlining its operations to concentrate on commercializing bioceramic technologies that have the potential to improve patient outcomes and enhance the performance of medical implants and devices. The sale of TA&T also reduces corporate liabilities by
“This sale represents an important milestone in our strategic realignment,” said Eric K. Olson, CEO of SINTX Technologies. “By divesting of these assets, we are fully committing our resources to the medical device market, where our expertise in advanced ceramics can have the greatest impact. This transaction not only enhances our financial flexibility but also supports our efforts to accelerate product development and commercialization efforts in healthcare.”
The Company remains dedicated to advancing its proprietary silicon nitride-based technologies, which have been used in human implants since 2008. This renewed emphasis on healthcare innovation underscores SINTX’s confidence in its core technologies and their ability to drive long-term value creation.
For more information, please visit www.sintx.com
About SINTX Technologies, Inc.
Located in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. For more information on SINTX Technologies or its materials platform, visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”) that are subject to a number of risks and uncertainties. Forward-looking statements can be identified by words such as: "anticipate," "believe," "project," "estimate," "expect," "strategy,” "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding operating efficiencies realized from the sale of TA&T, the benefits of our products for patients, our ability to successfully develop and commercialize new and existing products, our ability to generate long-term value, advancement of ceramic technologies and exploring new avenues for growth and innovation, and the potential to pursue growth opportunities and explore strategic opportunities.
Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, difficulty in commercializing ceramic technologies and development of new product opportunities. A discussion of other risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements can be found in SINTX’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the SEC on March 27, 2024, and in SINTX’s other filings with the SEC. SINTX undertakes no obligation to publicly revise or update the forward-looking statements to reflect events or circumstances that arise after the date of this report, except as required by law.
Business and Media Inquiries for SINTX:
SINTX Technologies
801.839.3502
IR@sintx.com
FAQ
How much will SINTX Technologies save annually from selling TA&T subsidiary?
What is the reduction in corporate liabilities for SINTX (SINT) from the TA&T sale?
Which company acquired SINTX Technologies' TA&T subsidiary?
What is SINTX Technologies' new strategic focus after the TA&T sale?
How long has SINTX's silicon nitride technology been used in human implants?
